medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2016, Number 3

<< Back Next >>

Ann Hepatol 2016; 15 (3)

Liver stiffness assessed by transient elastography in patients with β thalassaemia major

Ferraioli G, Lissandrin R, Tinelli C, Scudeller L, Bonetti F, Zicchetti M, Longo F, Murgia M, Bernuzzi S,Zecca M, Casula P, Piga A, Filice C

Language: English
References: 40
Page: 410-417
PDF size: 173.72 Kb.


ABSTRACT

Rationale for the study. This cross-sectional multicenter study was conducted to investigate any difference in liver stiffness measurements (LSM), evaluated by transient elastography, between patients affected by β thalassaemia major, with and without hepatitis C virus (HCV) infection, and healthy blood donors (controls). Secondary aim was to assess any correlation between transient elastography and serum ferritin, liver magnetic resonance imaging (MRI) T2* or superconductive quantum interference device (SQUID) liver susceptometry values. Materials and methods. The study involved three centers. Transient elastography and MRI T2* examinations were performed in all centers. SQUID liver susceptometry was performed in center1 and center2. T-test for independent data or Mann-Whitney U test was used to analyse differences between two groups. Univariate Pearson’s r coefficient was used to test correlations between liver stiffness measurements and all other variables. Results. In a study with 119 patients and 183 controls, patients who had never been infected with HCV showed significantly higher LSMs than controls [5.7 (95% CI, 5.2-6.2) kPa vs. 4.3 (95% CI, 4.1-4.4) kPa, p ‹ 0.0001]. A moderate correlation between LSMs and ferritin values, adjusted for gender and age, was found in patients (r = 0.49, p ‹ 0.0001) but not in controls (r = -0.22, p = 0.6). No correlation between LSMs and MRI T2* or SQUID liver susceptometry values was observed. In conclusion, compared to controls β thalassaemia major patients had a significant increase in LSMs independently from HCV infection.


REFERENCES

  1. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G, Forni GL, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent betathalassemia. A multicenter study of 117 cases. Haematologica 2004; 89: 1179-86.

  2. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89: 739-61.

  3. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR; Thalassemia Clinical Research Network. Complications of betathalassemia major in North America. Blood 2004; 104: 34-9.

  4. Telfer PT, Prestcott E, Holden S, Walker M, Hoffbrand AV, Wonke B. Hepatic iron concentration combined with longterm monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 2000; 110: 971-7.

  5. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21.

  6. Emond MJ, Bronner MP, Carlson TH, Lin M, Labbe RF, Kowdley KV. Quantitative study of the variability of hepatic iron concentrations. Clin Chem 1999; 45: 340-6.

  7. St Pierre TG, Clark PR, Chua-anusorn W, Fleming AJ, Jeffrey GP, Olynyk JK, Pootrakul P, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005; 105: 855-61.

  8. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, Mc-Gee A, Martin M, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Eng J Med 1994; 331: 574-8.

  9. Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini MD, Del Vecchio GC, Romeo MA, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-93.

  10. Hearnshaw S, Thompson NP, McGill A. The epidemiology of hyperferritinaemia. World J Gastroenterol 2006; 12: 5866-9.

  11. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, et al. Iron levels in hepatocytes and portal tract cells predict progression and outcome of patients with advanced chronic hepatitis C. Gastroenterology 2011; 140: 1490-500.

  12. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-9.

  13. Wood JC, Enriquez C, Ghugre N, Tyzka JM, Carson S, Nelson MD, Coates TD. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle-cells disease patients. Blood 2005; 106: 1460-5.

  14. Brittenham GM, Farrell DE, Harris JW, Feldman ES, Danish EH, Muir WA, Tripp JH, et al. Magnetic-susceptibility measurement of human iron stores. N Eng J Med 1982; 307: 1671-5.

  15. Fischer R, Tiemann CD, Engelhardt R, Nielsen P, Dürken M, Gabbe EE, Janka GE. Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry. Am J Hematol 1999; 60: 289-99.

  16. Fischer R, Longo F, Nielsen P, Engelhardt R, Hider RC, Piga A. Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with betathalassaemia major: application of SQUID biomagnetic liver susceptometry. Br J Haematol 2003; 121: 938-48.

  17. Fischer R, Harmatz PR. Non-invasive assessment of tissue iron overload. Hematology. Am Soc Hematol Educ Program 2009; 215-21.

  18. Nielsen P, Engelhardt R, Duerken M, Janka GE, Fischer R. Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. Transfus Sci 2000; 23: 257-8.

  19. Fung EB, Fischer R, Pakbaz Z, Fagaly RL, Vichinsky E, Starr TN, Ewing T, et al. The new SQUID biosusceptometer at Oakland: first year of experience. Neurol Clin Neurophysiol 2004; 2004: 5.

  20. Busca A, Falda M, Manzini P, D’Antico S, Valfrè A, Locatelli F, Calabrese R, et al. Iron overload in patients receiving allogeneic hematopoietic stem cell transplantation: quantification of iron burden by a superconducting quantum interference device (SQUID) and therapeutic effectiveness of phlebotomy. Biol Blood Marrow Transplant 2010; 16: 115-22.

  21. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-13.

  22. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Lédinghen V, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005; 41: 48-54.

  23. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.

  24. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-9.

  25. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835-47.

  26. Berzigotti A, Castera L. Update on ultrasound imaging of liver fibrosis. J Hepatol 2013; 59: 180-2.

  27. Fraquelli M, Cassinerio E, Roghi A, Rigamonti C, Casazza G, Colombo M, Massironi S, et al. Transient elastography in the assessment of liver fibrosis in adult thalassemia patients. Am J Hematol 2010; 85: 564-8.

  28. Mirault T, Lucidarme D, Turlin B, Vandevenne P, Gosset P, Ernst O, Rose C. Non-invasive assessment of liver fibrosis by transient elastography in post transfusional iron overload. Eur J Haematol 2008; 80: 337-40.

  29. Di Marco V, Bronte F, Cabibi D, Calvaruso V, Alaimo G, Borsellino Z, Gagliardotto F, et al. Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. Br J Haematol 2010; 148: 476-9.

  30. Poustchi H, Eslami M, Ostovaneh MR, Modabbernia A, Saeedian FS, Taslimi S, George J, et al. Transient elastography in hepatitis C virus-infected patients with beta-thalassemia for assessment of fibrosis. Hepatol Res 2013; 43: 1276-83.

  31. Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Rondanelli M, Perani G, Bernuzzi S, et al. Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis. Hepatol Int 2014; 8: 576-81.

  32. Di Tucci AA, Matta G, Deplano S, Gabbas A, Depau C, Derudas D, Caocci G, et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008; 93: 1385-8.

  33. Sirli R, Sporea I, Tudora A, Deleanu A, Popescu A. Transient elastographic evaluation of subjects without known hepatic pathology: does age change the liver stiffness? J Gastrointestin Liver Dis 2009; 18: 57-60.

  34. Corpechot C, El Naggar A, Poupon R. Gender and liver: is the liver stiffness weaker in weaker sex? Hepatology 2006; 44: 513-4.

  35. Roulot D, Czernichow S, Le Clésiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: influence of gender and metabolic syndrome. J Hepatol 2008; 48: 606-13.

  36. Musallam KM, Motta I, Salvatori M, Fraquelli M, Marcon A, Taher AT, Cappellini MD. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. Blood Cells Mol Dis 2012; 49: 136-9.

  37. Sinakos E, Perifanis V, Vlachaki E, Tsatra I, Raptopoulou-Gigi M. Is liver stiffness really unrelated to liver iron concentration? Br J Haematol 2010; 150: 247-28.

  38. Fanni D, Fanos V, Gerosa C, Piras M, Dessi A, Atzei A, Van EP, et al. Effects of iron and copper overload on the human liver: an ultrastructural study. Curr Med Chem 2014; 21: 3768-74.

  39. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101: 91-6.

  40. Bonkovsky HL, Banner B F, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.




2020     |     www.medigraphic.com